Skip to main content
Erschienen in: Clinical Rheumatology 11/2019

15.07.2019 | Original Article

Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma—do South Asians have a more aggressive disease?

verfasst von: Ramya Janardana, Aswin M Nair, Ajit K Surin, John Anthony Jude Prakash, Mahasampath Gowri, Debashish Danda

Erschienen in: Clinical Rheumatology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Aim and methods

A single-centre retrospective study was conducted using electronic medical records (EMR) of inpatients and outpatients with the diagnosis of “scleroderma” or “systemic sclerosis” visiting our clinic over the preceding 5 years.

Results

A total of 327 patients’ charts met our selection criteria; 301 were females. The median (IQR (inter quartile range)) age at onset of first non-Raynaud’s symptom was 34.67 (27–43) years and median (IQR) disease duration prior to presentation to our department was 2.5 (1–5) years. Of these, 310 (94.8%) belonged to diffuse systemic sclerosis variety, 13 (4%) had limited systemic sclerosis, and 4 (1.2%) were of sine scleroderma type. A total of 289/302 (95.7%) patients were positive for ANA; of them, 245/327 (74.9%) were Scl-70 antibody-positive and 4% were CENP antibody-positive. Interstitial lung disease (ILD) was present in 288/327 (88.1%) patients. Among patients with available baseline forced vital capacity (FVC) data, 20% had a normal lung function and 28.4% had severe restriction. Pulmonary hypertension as assessed by echocardiography was present in 8.1% of patients. A significant association of Scl-70 antibody positivity with the presence of interstitial lung disease (ILD) (p = 0.000) and pulmonary hypertension (p = 0.035) was seen. On the other hand, presence of CENP antibody showed a protective trend against muscle weakness and/or muscle enzyme elevation (p = 0.052). Presence of arthritis was protective against development of digital ulceration (p = 0.021) and PAH (0.004). Patients younger than 40 years of age had significantly higher frequency of Scl-70 positivity (p = 0.038), whereas CENP antibody positivity was more likely in those aged > 40 years (p = 0.002).

Conclusion

Younger age of onset and high prevalence of Scl-70 antibody are unique South Asian features common with large Indian, Thai, and Chinese series. High prevalence of ILD is a feature common to Indian and Chinese series. Strong correlation of Scl-70 antibody with younger age and pulmonary hypertension were unique features of our cohort.

Key Points

• Asian Indian scleroderma patients are younger by 2 decades compared to Caucasian series.
• Higher prevalence of Scl-70 antibody, its association with young age, interstitial lung disease and pulmonary hypertension are features of our cohort.
High prevalence of interstitial lung disease (88.1%) was noted ; among those with baseline spirometry data (141/327), two thirds(66%) had moderate to severe restriction.
Younger age at onset, higher prevalence of Scl-70 antibody are features common to other Indian, Thai and Chinese series.
Literatur
2.
5.
Zurück zum Zitat Kumar A, Malaviya AN, Tiwari SC, Singh RR, Kumar A, Pande JN (1990) Clinical and laboratory profile of systemic sclerosis in northern India. J Assoc Physicians India 38(10):765–768PubMed Kumar A, Malaviya AN, Tiwari SC, Singh RR, Kumar A, Pande JN (1990) Clinical and laboratory profile of systemic sclerosis in northern India. J Assoc Physicians India 38(10):765–768PubMed
7.
Zurück zum Zitat Krishnamurthy V, Porkodi R, Ramakrishnan S, Rajendran CP, Madhavan R, Achuthan K, Chandrasekaran AN (1991) Progressive systemic sclerosis in south India. J Assoc Physicians India 39(3):254–257PubMed Krishnamurthy V, Porkodi R, Ramakrishnan S, Rajendran CP, Madhavan R, Achuthan K, Chandrasekaran AN (1991) Progressive systemic sclerosis in south India. J Assoc Physicians India 39(3):254–257PubMed
8.
Zurück zum Zitat Nishioka K, Katayama I, Kondo H, Shinkai H, Ueki H, Tamaki K et al (1996) Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J Dermatol 23(JAPAN PT-Comparative Study PT-Journal Article PT-Research Support, Non-U.S. Gov’t LG-English DC-19970121 OVID MEDLINE UP 20151216):677–682CrossRef Nishioka K, Katayama I, Kondo H, Shinkai H, Ueki H, Tamaki K et al (1996) Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J Dermatol 23(JAPAN PT-Comparative Study PT-Journal Article PT-Research Support, Non-U.S. Gov’t LG-English DC-19970121 OVID MEDLINE UP 20151216):677–682CrossRef
14.
Zurück zum Zitat Medsger TAJ, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21(3 Suppl 29):S42–S46PubMed Medsger TAJ, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21(3 Suppl 29):S42–S46PubMed
21.
Zurück zum Zitat Wu C, Wang Q, Xu D, Li M, Hou Y, Zeng X (2014) The prevalence and clinical significance of arthritis in patients with systemic sclerosis. Zhonghua Nei Ke Za Zhi 53(6):460–463. in Chinese Wu C, Wang Q, Xu D, Li M, Hou Y, Zeng X (2014) The prevalence and clinical significance of arthritis in patients with systemic sclerosis. Zhonghua Nei Ke Za Zhi 53(6):460–463. in Chinese
Metadaten
Titel
Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma—do South Asians have a more aggressive disease?
verfasst von
Ramya Janardana
Aswin M Nair
Ajit K Surin
John Anthony Jude Prakash
Mahasampath Gowri
Debashish Danda
Publikationsdatum
15.07.2019
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 11/2019
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04659-2

Weitere Artikel der Ausgabe 11/2019

Clinical Rheumatology 11/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.